Masimo (NASDAQ: MASI) is a global medical technology company that develops and manufactures innovative noninvasive patient monitoring technologies, including medical devices and a wide array of sensors. A key medical technology innovator, Masimo is responsible for the invention of award-winning noninvasive technologies that are revolutionizing patient monitoring, including Masimo SET® pulse oximetry, Masimo Rainbow Pulse CO-Oximetry and new Masimo noninvasive and continuous total hemoglobin (SpHb™) monitoring technology. The recent introduction of the first-and-only FDA-cleared technology that noninvasively and continuously measures total hemoglobin without a painful needle stick and invasive blood draw is expected to open new markets and significantly expand the company’s growth opportunities.
Joe Kiani founded Masimo in 1989 as a private «garage start-up» company because he was convinced that the use of adaptive signal processing in the measurement of physiological parameters could solve the problems of low perfusion and motion, which had long plagued in-vivo monitoring and especially pulse oximetry. Today, Masimo has grown into a successful publicly-traded medical technology company employing over 2,500 people worldwide with product revenues that have increased 4-fold in the last five years. In addition, with technology license and OEM agreements with leading patient monitoring manufacturers spanning the globe-such as Atom, Datascope, GE Medical, Medtronic, Philips, Spacelabs and Zoll, among others. Masimo is not only the inventor of measure-through motion and low perfusion pulse oximetry and Pulse CO-Oximetry technologies, but is also the market-leading pulse oximetry technology solution.
